Dermata Therapeutics, Inc. (DRMA) Stock Forecast
DRMA analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 1 analysts
- Price target
- $4.00 average of analyst targets
- Upside to target
- +365.1% from the latest close
- Next earnings
- November 13, 2026
- 52-week range
- $0.66 – $4.20
DRMA analyst ratings
1 analystsNumber of analysts at each rating.
DRMA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DRMA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.55 | −$0.55 | −$0.55 | −$1.65 | +66.7% | 1 |
| Current fiscal year (2026) | −$2.17 | −$2.17 | −$2.17 | −$8.16 | +73.4% | 1 |
| Next fiscal year (2027) | −$1.43 | −$1.43 | −$1.43 | −$2.17 | +34.1% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DRMA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $25,000 | $25,000 | $25,000 | 0.0% | 1 |
| Current fiscal year (2026) | $100,000 | $100,000 | $100,000 | 0.0% | 1 |
| Next fiscal year (2027) | $750,000 | $750,000 | $750,000 | +650.0% | 1 |
DRMA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DRMA revenue: reported and forecast
DRMA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.61 | −$0.63 | −$0.63 | −$0.63 | −$0.55 | −9.8% | 1 up · 0 down |
| Current fiscal year (2026) | −$2.20 | −$2.21 | −$2.21 | −$2.21 | −$2.17 | −1.4% | 1 up · 0 down |
| Next fiscal year (2027) | −$1.49 | −$1.52 | −$1.52 | −$1.52 | −$1.43 | −4.0% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DRMA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DRMA beat in 8 of 12.
What analysts expect from DRMA
1 analysts cover Dermata Therapeutics; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.00, 365.1% above the latest close of $0.86. Analysts expect earnings of −$2.17 per share for 2026, +73.4% from a year earlier. For 2027 the average estimate is −$1.43 per share on revenue of $0.8 million. Dermata Therapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: DRMA income statement, DRMA key metrics, DRMA chart. See the DRMA stock overview for the latest quote and news.
DRMA forecast FAQ
What is Dermata Therapeutics's price target?
The average analyst price target for Dermata Therapeutics is $4.00, 365.1% above the latest close of $0.86.
Is Dermata Therapeutics a buy, hold or sell?
Of 1 analysts covering Dermata Therapeutics, 0 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Dermata Therapeutics's EPS forecast?
Analysts forecast −$2.17 per share for 2026 (range −$2.17 to −$2.17); for 2027 the estimate is −$1.43.
What is Dermata Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $0.1 million, growth of 0.0%; for 2027 it is $0.8 million.
When does Dermata Therapeutics report earnings?
Dermata Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
Does Dermata Therapeutics usually beat earnings estimates?
Dermata Therapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.